Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Moleculin Biotech announced that an abstract featuring pooled cardiac safety data for its lead drug candidate Annamycin has been accepted for poster presentation at the 2026 ASCO Annual Meeting. The analysis of 90 patients showed no statistically significant change in left ventricular ejection fraction (LVEF) from baseline, with a mean difference of -0.12% (p=0.84), despite median cumulative doses exceeding conventional anthracycline limits.
Key figures
- Drug Name
- Annamycin (L-Annamycin / naxtarubicin)
- Phase Of Trial
- Phase 2b/3
- Lvef p value
- 0.84
- Patients with lvef data
- 78
- Lvef mean difference pct
- -0.12
- Patients in safety review
- 90
- Previous phase 1b 2 cr rate
- 50%
- Age lvef correlation p value
- 0.73
- Median cumulative dose mg m2
- 660
- Previous phase 1b 2 crc rate
- 60%
- Dose lvef correlation p value
- 0.12
- Previous phase 1b 2 median os months
- 12.39
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.